Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease

Studies of rodent models of Alzheimer's disease (AD) and of human tissues suggest that the retinal changes that occur in AD, including the accumulation of amyloid beta (Abeta), may serve as surrogate markers of brain Abeta levels. As Abeta has a wavelength-dependent effect on light scatter, we investigate the potential for in vivo retinal hyperspectral imaging to serve as a biomarker of brain Abeta. Significant differences in the retinal reflectance spectra are found between individuals with high Abeta burden on brain PET imaging and mild cognitive impairment (n = 15), and age-matched PET-negative controls (n = 20). Retinal imaging scores are correlated with brain Abeta loads. The findings are validated in an independent cohort, using a second hyperspectral camera. A similar spectral difference is found between control and 5xFAD transgenic mice that accumulate Abeta in the brain and retina. These findings indicate that retinal hyperspectral imaging may predict brain Abeta load.

Mots clés

Aged; Alzheimer Disease/diagnostic imaging/metabolism; Amyloid beta-Peptides/chemistry/metabolism; Animals; Biomarkers/chemistry/metabolism; Brain/diagnostic imaging/metabolism; Cohort Studies; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Positron-Emission Tomography; Retina/diagnostic imaging/metabolism; Tomography, Optical Coherence/methods